Fertilisers and Chemicals Travancore Ltd (FACT): India's Oldest Fertilizer Pioneer at a Crossroads

A Legacy Giant in Indian Agriculture

Fertilisers and Chemicals Travancore Ltd (NSE: FACT | BSE: 590024) is one of India's most storied industrial enterprises and the first large-scale fertiliser plant in the country. Incorporated in 1943 and headquartered at Udyogamandal, Kochi, Kerala, FACT has been a cornerstone of India's agricultural transformation for over eight decades. The company operates under the administrative control of the Department of Fertilizers, Ministry of Chemicals & Fertilizers, Government of India, with the central government holding a dominant 90.00% stake as of March 2026.

As of the latest trading session on 1 June 2026, FACT's shares closed at ₹869 on the NSE, down 0.80% for the day, commanding a market capitalisation of ₹56,208 crore. This places the company among India's mid-cap public sector enterprises, valued far beyond what its modest financial fundamentals might suggest — a phenomenon driven by sectoral optimism, government policy tailwinds, and speculative retail interest.

This comprehensive research report examines FACT's business model, financial trajectory, peer positioning, and the key factors that investors must weigh before taking a position in this government-owned fertilizer manufacturer.

Business Overview: What FACT Does

FACT manufactures and sells a diversified portfolio of products spanning the fertilizer and chemical segments:

• Complex Fertilisers — primarily Factamfos, the company's flagship complex fertilizer brand
• Straight Fertilisers — including Ammonium Sulphate
• Organic Fertilisers and Biofertilisers
• Imported Fertilisers — including Muriate of Potash (MOP) distributed under government subsidy schemes
• Caprolactam — a critical chemical intermediate used in manufacturing Nylon Tyre Cord, Nylon Filament Yarn, and Engineering Plastics
• Bagged Gypsum — a by-product sold to the construction and agricultural sectors

This dual revenue stream from fertilizers and specialty chemicals has historically provided FACT with some diversification, though fertilizer sales dominate the revenue mix by a wide margin. The caprolactam segment, while value-added, has been volatile and has not consistently contributed meaningfully to profitability.

The company's products are sold predominantly in the southern and western states of India, with a strong distribution network in Kerala, Tamil Nadu, Karnataka, Andhra Pradesh, and Maharashtra. As a government entity, FACT also participates in the Nutrient-Based Subsidy (NBS) regime and other centrally-sponsored fertilizer distribution programs.

Financial Performance: A Story of Volatility

Revenue Trajectory

FACT's top-line growth has been erratic over the past decade, reflecting the cyclicality of the fertilizer industry, raw material price fluctuations, and plant operational issues:

• FY2015 Sales: ₹1,981 crore
• FY2020 Sales: ₹2,770 crore
• FY2023 Sales: ₹6,198 crore (peak, driven by elevated fertilizer prices globally)
• FY2024 Sales: ₹5,051 crore (decline as prices normalised)
• FY2025 Sales: ₹4,051 crore (further contraction)
• TTM Sales: ₹5,293 crore

The 5-year compounded sales growth stands at approximately 8%, while the 3-year growth is negative at -3%, reflecting the post-surge normalisation. The TTM growth of 30% offers a glimmer of recovery, but sustainability remains uncertain.

Looking at recent quarterly performance:

• Q3 FY2026 (Dec 2025): Sales of ₹1,568 crore, up sharply from ₹949 crore in Q2 FY2026
• Q2 FY2026 (Sep 2025): Sales of ₹1,629 crore
• Q4 FY2025 (Mar 2025): Sales of ₹1,053 crore
• Q1 FY2026 (Jun 2025): Sales of ₹1,043 crore

The quarterly sales trajectory shows significant seasonality, with Q2 and Q3 (monsoon and rabi sowing season) typically being the strongest quarters for fertilizer demand.

Profitability: The Core Concern

This is where FACT's investment case becomes deeply challenging. Despite revenues exceeding ₹4,000 crore annually, the company's profitability has deteriorated dramatically:

• FY2020 Net Profit: ₹976 crore (exceptional year)
• FY2023 Net Profit: ₹613 crore
• FY2024 Net Profit: ₹128 crore
• FY2025 Net Profit: ₹41 crore
• TTM Net Profit: ₹28 crore

The 5-year profit growth of 45% is misleading, as it starts from a low base. The 3-year profit growth of -63% and TTM decline of -82% paint the true picture of rapidly eroding earnings.

Operating margins have collapsed:

• FY2023 OPM: 12%
• FY2024 OPM: 7%
• FY2025 OPM: 2%
• TTM OPM: 2%
• Q3 FY2026 OPM: -3% (operating loss!)

The most alarming data point is the Q3 FY2026 (Dec 2025) quarterly result, where FACT reported:

• Sales: ₹1,568 crore
• Expenses: ₹1,611 crore
• Operating Profit: -₹43 crore (negative)
• Net Profit: -₹68 crore (loss)

This is a company generating over ₹5,000 crore in annual sales but struggling to turn a profit. The interest burden alone is ₹62 crore per quarter (₹246 crore annually), which is constant regardless of revenue levels.

Earnings Quality: A Major Red Flag

A critical concern is the quality of FACT's reported earnings. Of the ₹28 crore TTM net profit, a substantial portion comes from other income of ₹219 crore. This other income — likely comprising interest on government deposits, subsidies, and sundry non-operating items — is masking what would otherwise be a significant operating loss. Stripping out other income, FACT's core operations are barely profitable or loss-making in recent quarters.

Balance Sheet: Heavily Leveraged

FACT's balance sheet reveals a company carrying significant debt:

• Equity Capital: ₹647 crore (unchanged for over a decade)
• Reserves: ₹728 crore (as of Sep 2025) — a dramatic improvement from the negative reserves of -₹1,499 crore in FY2015
• Borrowings: ₹3,837 crore (as of Sep 2025), up sharply from ₹1,805 crore in FY2025
• Total Assets: ₹6,677 crore

The borrowings have nearly doubled from ₹1,805 crore in March 2025 to ₹3,837 crore by September 2025, which is a concerning development. This ₹2,032 crore increase in just six months suggests working capital stress or capex financing.

Fixed Assets stand at ₹948 crore with an additional ₹243 crore in Capital Work in Progress (CWIP), indicating ongoing capital expenditure. Investments of ₹158 crore and other assets of ₹5,328 crore (which include large receivables from government subsidy receivables) round out the asset side.

The book value per share is a mere ₹21.2, meaning the stock at ₹869 trades at approximately 40.9 times book value — an extraordinarily rich multiple for a company with such thin margins.

Cash Flow Analysis

FACT's cash flow statement tells a mixed story:

• FY2025 Operating Cash Flow: ₹140 crore (positive but thin)
• FY2025 Investing Cash Flow: -₹282 crore (capex continues)
• FY2025 Financing Cash Flow: -₹75 crore
• FY2025 Free Cash Flow: -₹13 crore (negative!)

The CFO/Operating Profit ratio of 147% for FY2025 is positive, meaning the company converted its accounting profits into cash efficiently. However, with operating profits of just ₹95 crore and capex of ₹282 crore, free cash flow turned negative.

Historically, FACT's best free cash flow years were:

• FY2020: ₹1,186 crore
• FY2021: ₹988 crore
• FY2023: ₹556 crore

The company generated ₹182 crore of free cash flow in FY2015 but has seen wide swings since then. The current trajectory of rising borrowings and negative free cash flow is unsustainable in the long run.

Valuation: Extraordinarily Expensive

By virtually every valuation metric, FACT is priced for perfection — something its fundamentals emphatically do not deliver:

The P/E ratio of 3,795x is among the highest in the entire Indian market and reflects earnings that are essentially at break-even levels. Any small change in earnings creates enormous P/E swings, making this metric unreliable for valuation purposes.

At ₹869, the stock is 40.9 times its book value of ₹21.2. This valuation premium is largely driven by:

1. Government ownership creating a perception of safety and policy support
2. Sector re-rating — the fertilizer sector has seen massive valuation expansion since 2020
3. Retail investor enthusiasm — shareholder count surged from 16,124 in FY2017 to 68,699 by March 2026
4. Low free float — with 90% government holding and ~8.96% in government institutions, only about 1% is freely traded, creating supply scarcity

Shareholding Pattern: Government Dominance

The shareholding pattern of FACT is remarkably concentrated:

• Promoters (Government of India): 90.00% (stable since at least FY2017)
• FIIs: 0.21% (marginal; increased from near-zero in recent years)
• DIIs: 0.06% (down from 8.61% in Q1 FY2026 — a significant sell-down)
• Government: 8.96% (this is separate from promoter holdings, likely EPFO/SBI/etc.)
• Public/Retail: 0.77%

The public holding of just 0.77% with 68,699 shareholders means the effective free float is extraordinarily small. This low float has been a key driver of the stock's price appreciation, as even modest buying pressure can move the stock significantly.

Notably, DIIs sold down their stake from 8.61% to 0.06% between September 2025 and December 2025 — a massive institutional exit that coincided with the company's deteriorating financial performance. This is a significant bearish signal that retail investors should heed.

Peer Comparison: FACT Stands Out — For the Wrong Reasons

Comparing FACT with fertilizer sector peers reveals a stark valuation disconnect:

FACT trades at 3,795x P/E while the sector median P/E is 16.92x. It trades at a higher market cap than Coromandel International — a far more profitable and diversified company. FACT reported a quarterly net loss of ₹67.90 crore while every single peer reported profits. Its ROCE of 8.65% is below the sector median of 15.19%.

By every comparative metric, FACT is the most expensive stock in the fertilizer sector — and it's expensive while being the least profitable. This valuation gap can only be justified if one believes in a massive turnaround in operations or a significant government policy catalyst.

Growth Rates: Price vs. Fundamentals Disconnect

Sales Growth

• 10-Year CAGR: 7%
• 5-Year CAGR: 8%
• 3-Year CAGR: -3%
• TTM: 30%

Profit Growth

• 10-Year CAGR: 7%
• 5-Year CAGR: 45%
• 3-Year CAGR: -63%
• TTM: -82%

Stock Price CAGR

• 10-Year: 43%
• 5-Year: 48%
• 3-Year: 41%
• 1-Year: -2%

The 43% stock price CAGR over 10 years versus 7% sales CAGR and 7% profit CAGR tells the entire story. The stock has re-rated massively, driven by narrative and liquidity rather than fundamental earnings growth. The 5-year stock CAGR of 48% versus a -63% 3-year profit CAGR shows that price and profits have completely diverged.

Dividend History: Inconsistent but Improving

FACT has been an inconsistent dividend payer due to its history of losses:

• FY2015 to FY2021: 0% dividend payout (no dividends during loss-making years)
• FY2023: 11% payout
• FY2024: 49% payout
• FY2025: 61% payout

The 61% payout in FY2025 is notable given that the company earned just ₹41 crore in net profit. At the current price of ₹869, the dividend yield is a negligible 0.02%. The company has been maintaining a healthy dividend payout of 40.2% over recent years, but this is more a reflection of government dividend extraction policy than financial strength.

Working Capital Dynamics

FACT operates with negative working capital days (currently -239 days), which is characteristic of fertilizer companies that receive advance payments from dealers and have long payable cycles. Key metrics:

• Debtor Days: 26 (very low; government subsidy receivables may be classified elsewhere)
• Inventory Days: 128
• Days Payable: 60
• Cash Conversion Cycle: 94 days

The negative working capital days suggest the company benefits from upfront collections, though the rising borrowings suggest this advantage is not translating into cash generation.

Key Risks and Concerns

1. Valuation Bubble

At 3,795x P/E and 40.9x book value, FACT is priced to deliver flawless execution — something it has never demonstrated. Any reversion to sector-average multiples would imply a 95-99% price decline.

2. Deteriorating Operations

Operating margins have collapsed from 17% (FY2021) to -3% (Q3 FY2026). The company is now generating operating losses on over ₹1,500 crore of quarterly sales.

3. Rising Debt

Borrowings surged from ₹1,805 crore to ₹3,837 crore in just six months (Mar 2025 to Sep 2025). Annual interest costs of ₹246 crore are a fixed burden that eats into thin margins.

4. Institutional Exit

DIIs sold down from 8.61% to 0.06% between September and December 2025. This 8.55 percentage point institutional exit is a major red flag.

5. Government Policy Dependence

FACT's profitability is heavily dependent on government subsidy policies, raw material pricing norms, and urea/complex fertilizer pricing — all of which are politically determined and subject to sudden change.

6. Low Free Float

With only 0.77% public holding, the stock is vulnerable to sharp price swings on low volumes. This creates liquidity risk for investors.

7. Caprolactam Segment Uncertainty

The specialty chemicals segment (caprolactam) has been volatile and has not provided consistent diversification benefits.

Potential Catalysts and Positives

1. Government Support

As a 90% government-owned entity, FACT is unlikely to face existential financial distress. The government has historically provided financial support through equity infusions and favorable policies.

2. Capacity Expansion

The ₹243 crore CWIP and rising fixed assets suggest ongoing capacity investments that could improve future earnings if executed well.

3. Strong ROE Track Record

Despite recent weakness, FACT has delivered a 3-year average ROE of 27.4%, suggesting the business can generate attractive returns when market conditions are favorable.

4. Sector Tailwinds

India's fertilizer sector benefits from a growing population, government focus on food security, and the push toward self-sufficiency in fertilizer production. The Nutrient-Based Subsidy (NBS) regime provides some pricing stability.

5. Recovery Potential

The TTM sales of ₹5,293 crore (30% growth) suggest a revenue recovery is underway. If margins normalise even partially, earnings could improve significantly from current depressed levels.

6. Stock Price Momentum

Despite recent weakness (-2% over 1 year), FACT has delivered 41% CAGR over 3 years and 48% over 5 years, rewarding long-term holders with exceptional returns.

Who Should Consider FACT?

For aggressive, risk-tolerant investors who believe in:

• Government policy support for the fertilizer sector
• A turnaround in operating margins
• Continued sectoral re-rating despite valuation concerns
• The low-float, high-beta characteristic of the stock

FACT could be a speculative bet on the Indian fertilizer sector's long-term growth story. The stock has delivered extraordinary returns over the past decade (43% CAGR) despite inconsistent fundamentals.

For conservative investors, FACT is best avoided at current levels:

• The P/E of 3,795x offers no margin of safety
• Operating losses in recent quarters
• Rising debt and negative free cash flow
• Institutional selling (DIIs exited massively)
• Negligible dividend yield of 0.02%

Conclusion

Fertilisers and Chemicals Travancore Ltd represents one of the most fascinating case studies in Indian equity markets — a company with eight decades of history, ₹5,000+ crore in annual sales, and a ₹56,000+ crore market cap that struggles to earn meaningful profits. The stock has been a phenomenal wealth creator (48% CAGR over 5 years) despite deteriorating fundamentals, driven by government ownership, low free float, and sectoral optimism.

However, the ground reality is sobering: operating margins of 2%, a quarterly loss of ₹68 crore, borrowings of ₹3,837 crore, and a book value of just ₹21.2 supporting a stock price of ₹869. The valuation disconnect between price and fundamentals has rarely been this extreme in the Indian fertilizer sector.

Investors must ask themselves: is this a turnaround story where government backing and sectoral tailwinds will eventually justify the valuation? Or is this a valuation bubble sustained by low float and retail enthusiasm that could deflate sharply when sentiment shifts?

The data suggests caution. While FACT's legacy and government backing provide a floor under the business, the stock at ₹869 is pricing in a future that the company's current financials are nowhere close to delivering. At a P/E of 3,795x and P/BV of 40.9x, investors are paying an extraordinary premium for a company that reported a net loss in the latest quarter.

For those already holding FACT from lower levels, the 43% 10-year CAGR has been a remarkable ride. For new investors, the risk-reward calculus at current levels demands either a strong conviction in a dramatic operational turnaround or an acceptance that this is a momentum-driven trade rather than a fundamental investment.